Skip to content
HowShorted

MYRIAD GENETICS INC short interest in 2019

In 2019, MYRIAD GENETICS INC's disclosed short interest ran from 18.84% of shares outstanding on 15 Jan 2019 to 18.37% on 31 Dec 2019, a change of -0.47 percentage points. The year's high was 21.89% on 29 Mar 2019 and its low 13.35% on 30 Aug 2019, averaging 17.82% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 29.64 days on 30 Apr 2019. Full history: MYRIAD GENETICS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for MYRIAD GENETICS INC in 2019

2019 in figures

Start of year
18.84% (15 Jan 2019)
End of year
18.37% (31 Dec 2019)
Change
-0.47 pp
High
21.89% (29 Mar 2019)
Low
13.35% (30 Aug 2019)
Average
17.82%
Highest days to cover
29.64 (30 Apr 2019)
SEC filings marked
8

Every report in 2019

MYRIAD GENETICS INC short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 201918.84%11.56
31 Jan 201920.00%18.00
15 Feb 201920.65%14.61results (8-K), 10-Q filed
28 Feb 201920.72%16.67
15 Mar 201921.36%14.25
29 Mar 201921.89%18.27
15 Apr 201921.58%27.38
30 Apr 201921.26%29.64
15 May 201921.12%12.68results (8-K), 10-Q filed
31 May 201919.64%11.67
14 Jun 201919.45%17.18
28 Jun 201918.92%9.24
15 Jul 201917.84%20.16
31 Jul 201917.02%17.27
15 Aug 201913.50%2.8910-K filed, results (8-K)
30 Aug 201913.35%9.51
13 Sep 201914.12%11.20
30 Sep 201916.12%7.35
15 Oct 201914.46%21.53
31 Oct 201914.94%19.96
15 Nov 201914.88%4.58results (8-K), 10-Q filed
29 Nov 201913.84%18.90
13 Dec 201913.92%18.24
31 Dec 201918.37%11.73

See also: MYRIAD GENETICS INC's full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.